Critical Care Research: Mitoquinol and Oxidative Stress in Septic Shock

Written by Georgia Truman (MSc), Molecular and Cellular Biology. Reviewed by Dr. Siobhan Mitchell (PhD), Neuroscience. 

Septic shock involves severe and rapidly escalating oxidative stress alongside mitochondrial dysfunction, contributing to multi-organ failure and high mortality. Mitochondria are central to both the energy demands of immune response and the oxidative injury that characterises sepsis, making them a theoretically compelling target for adjunctive intervention in critically ill patients. This study investigated whether mitochondrial antioxidant supplementation could improve oxidative stress and clinical outcomes in adults with septic shock. 

Research Summary 

Evidence type: Randomised, double-blind, placebo-controlled pilot trial

Claim strength: Causal (biomarker endpoints), mixed

Population: 42 adults with septic shock

Intervention: Mitoquinol 20 mg twice daily vs placebo (period of 5 days)

Primary outcomes: SOFA score, oxidative stress biomarkers

Observed outcome: Improved antioxidant enzyme activity; reduced lipid peroxidation; no significant improvement in mortality or organ recovery

Causality: Supported for biomarker modulation

Primary source: Naunyn-Schmiedeberg's Archives of Pharmacology 

What the Study Observed

Participants with septic shock received Mitoquinol (20 mg twice daily) or placebo for five days in addition to standard critical care. Mitoquinol produced improvements in antioxidant enzyme activity and reductions in lipid peroxidation, confirming target engagement at the biochemical level. However, these changes did not translate into statistically significant improvements in SOFA scores, organ recovery, or mortality over the study period. 

What Are the Implications for Clinical Outcomes? 

The disconnect between biomarker improvement and clinical outcome in this study reflects the extraordinary complexity of septic shock as a therapeutic target. Oxidative stress is one of many interacting drivers of organ dysfunction in sepsis — alongside mitochondrial bioenergetic failure, microvascular thrombosis, immune dysregulation, and endothelial barrier breakdown — and correcting one component in isolation may be insufficient to shift organ function scores or mortality when the other pathological processes remain active and dominant. This is a common challenge in critical care intervention research and does not invalidate the biological signal: the fact that Mitoquinol measurably modulated oxidative stress in a population as severely ill as this is itself a meaningful finding. 

The five-day intervention window also deserves scrutiny. Septic shock is a rapidly evolving syndrome in which organ damage accrues over hours to days, and mortality often reflects injury sustained before any intervention can take effect. A five-day course may be both too short to reverse established organ dysfunction and too late to prevent the initial injury that drives the worst outcomes. The sample size of 42 participants also substantially limits the study's power to detect differences in mortality or organ recovery, where absolute event rates and individual variability are high. 

Taken together, these results suggest that Mitoquinol’s most plausible near‑term clinical value may be as a biologically active adjunct rather than a standalone “outcome‑shifting” therapy in established septic shock. In practical terms, the biomarker signal supports further evaluation in settings where mitochondrial injury is still evolving (earlier in the sepsis trajectory), and in study designs that link redox modulation to intermediate, clinically meaningful endpoints that sit closer to the mechanism—such as trajectories of vasopressor requirement, lactate clearance, or predefined organ-support–free days—before expecting detectable mortality differences. This framing also aligns with real-world critical care constraints: gastrointestinal absorption, perfusion, and dosing consistency can be highly variable in shock states, meaning that pharmacologic exposure (not just intent-to-treat assignment) may be a key determinant of whether biochemical effects can propagate into functional recovery.

Critical Considerations for Future Research 

Future trials should consider earlier intervention — ideally initiated at the point of sepsis recognition rather than at the point of shock — to test whether Mitoquinol can prevent mitochondrial injury before organ dysfunction is established rather than reversing it afterwards. Higher doses or intravenous formulations may also be warranted in critical care, where oral bioavailability and gastrointestinal absorption may be compromised by haemodynamic instability and reduced splanchnic perfusion. A larger, adequately powered multicentre trial incorporating biomarker-guided patient selection — enriching for participants with the highest baseline oxidative burden — would provide a more definitive test of whether the biochemical effects observed here translate into clinical benefit. 

Read the full paper: Mitoquinol in the treatment of septic shock

DOI: 10.1007/s00210-025-04526-9